The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

GLP1RA mimic the GLP-1 hormone in the body that helps control insulin and blood glucose levels and promotes feelings of satiety. GLP-1 binds to GLP1R on cells in the brain and pancreas.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

Citi analyst David Lebowitz initiated coverage of Viking Therapeutics (VKTX) with a Neutral rating and $38 price target Viking’s VK2735 is an ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

NLY01, a long-acting GLP-1 agonist, recently completed a 36-week ... incretin-based peptide drugs for obesity. Offering a new mechanism for treating fibrotic disease, TLY012 directly targets ...